Discontinuation of Infliximab Therapy in Patients with Crohn's Disease.

Sine Buhl,Casper Steenholdt,Jørn Brynskov,Katrine Risager Christensen, Maria Dorn-Rasmussen,Ole Østergaard Thomsen,Klaus Bendtzen, Tobias Wirenfeldt Klausen,Jens Frederik Dahlerup,Niels Thorsgaard,Jørgen Jahnsen,Akbar Molazahi,Natalia Pedersen,Jens Kjeldsen,Sven Almer,Eva Efsen Dahl,Ida Vind, Annett Gerhardt Cannon,Jan Marsal,Taina Sipponen,Jørgen Steen Agnholt, Hendrika Adriana Linda Kievit, Synnøve Louise Aure, Lars Martinsen,Svetlana Meisner,Jane Møller Hansen,Mark Andrew Ainsworth

NEJM evidence（2022）

引用 14|浏览16

暂无评分

摘要

Infliximab Discontinuation in Patients with Crohn's DiseaseThis randomized controlled trial explores infliximab withdrawal in patients with Crohn's disease in clinical, biochemical, and endoscopic remission with long-term infliximab maintenance therapy. Time to relapse was significantly shorter among patients who discontinued infliximab than among those who continued therapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要